Recursion Pharmaceuticals is combining high-throughput experimental biology, bioinformatics, and machine learning with advanced computational algorithms to discover new therapeutic opportunities for rare genetic diseases.
Recursion Pharmaceuticals LLC
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/recursion-pharmaceuticals” connections=”true” suffix=””]
Recursion Pharmaceuticals is working on the technology that combine innovative biological science with advanced computational algorithms to discover new therapeutic opportunities for rare genetic diseases.
In May 2018, Recursion received $546,000 grant from the Bill & Melinda Gates Foundation.
In Jun 2018, Recursion received credit of $20.5Mn from Square 1 Bank. The funds will help expand its platform to enable target discovery and new chemical entity discovery. Recursion is backed by several leading investors including Lux Capital, Data Collective Venture Capital, Mubadala Investment Company, and Obvious Ventures.
Oct 2017, Recursion has raised $60 million Data Collective led the round with support from the institutional investors.
In Dec. 2015, Recursion raised $2.6 Mn follow-on seed round led by Advantage Capital Partners. This investment brings Recursions total private investment since founding to just over $4 Mn, in addition to the companys more than $2 Mn in non-dilutive grant funding awarded by the NIH SBIR program and various private foundations.